- Home
- REVB vs NCPL Comparison
REVB vs NCPL Comparison
Compare REVB & NCPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- NCPL
- Stock Information
- Founded
- REVB 2020
- NCPL 1984
- Country
- REVB United States
- NCPL United States
- Employees
- REVB N/A
- NCPL N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- NCPL Investment Managers
- Sector
- REVB Health Care
- NCPL Finance
- Exchange
- REVB Nasdaq
- NCPL Nasdaq
- Market Cap
- REVB 1.4M
- NCPL 1.2M
- IPO Year
- REVB N/A
- NCPL N/A
- Fundamental
- Price
- REVB $0.34
- NCPL $1.77
- Analyst Decision
- REVB
- NCPL
- Analyst Count
- REVB 0
- NCPL 0
- Target Price
- REVB N/A
- NCPL N/A
- AVG Volume (30 Days)
- REVB 1.7M
- NCPL 631.0K
- Earning Date
- REVB 11-08-2024
- NCPL 12-24-2024
- Dividend Yield
- REVB N/A
- NCPL N/A
- EPS Growth
- REVB N/A
- NCPL N/A
- EPS
- REVB N/A
- NCPL N/A
- Revenue
- REVB N/A
- NCPL $1,702,723.00
- Revenue This Year
- REVB N/A
- NCPL N/A
- Revenue Next Year
- REVB N/A
- NCPL $101.16
- P/E Ratio
- REVB N/A
- NCPL N/A
- Revenue Growth
- REVB N/A
- NCPL N/A
- 52 Week Low
- REVB $0.32
- NCPL $1.41
- 52 Week High
- REVB $25.26
- NCPL $28.70
- Technical
- Relative Strength Index (RSI)
- REVB 27.29
- NCPL 44.63
- Support Level
- REVB $0.32
- NCPL $1.67
- Resistance Level
- REVB $0.47
- NCPL $2.10
- Average True Range (ATR)
- REVB 0.08
- NCPL 0.22
- MACD
- REVB -0.02
- NCPL -0.04
- Stochastic Oscillator
- REVB 3.40
- NCPL 11.49
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.